Curated news and analysis on clinical trials, drug approvals, and medical research.
Syndax Pharmaceuticals partnered with World Orphan Drug Alliance to launch a Managed Access Program for Revuforj in multiple regions. A price target was raised to $28 while maintaining a Buy rating.
A review in The Lancet highlights emerging long-acting injectable therapies for hypertension that could reduce treatment to two doses annually instead of daily pills, with several candidates now in late-stage clinical trials.
Ultragenyx Pharmaceutical announced positive long-term clinical data for UX111 gene therapy for Sanfilippo syndrome Type A, with up to 8.5 years of follow-up showing sustained biomarker reductions and functional improvements. The company resubmitted its BLA to the FDA in January 2026.
Three new computational approaches enhance molecular property prediction and drug design through advanced neural networks, multimodal learning, and thermodynamic analysis of receptor-ligand interactions.
The Southwest Florida Water Management District declared a Modified Phase II Water Shortage Order on Feb. 8 following a 13-inch rainfall deficit, imposing mandatory once-a-week watering restrictions and a 5 percent water usage surcharge across the region.
Clinical studies demonstrate GLP-1 receptor agonists like semaglutide and tirzepatide produce substantial weight loss when combined with lifestyle changes, with patients achieving mean reductions of 14.9% body weight over 68 weeks.
Tempus AI partners with Median Technologies to integrate FDA-cleared eyonis LCS lung cancer screening software into its Pixel platform, marking the first US distribution agreement for the diagnostic tool.
A population-based study of over 1.27 million births found SSRI antidepressants during pregnancy increase gestational diabetes risk but reduce preterm birth and low birth weight risks, with effects independent of maternal depression.
Investigation reveals prescription-only weight-loss drugs Mounjaro and Wegovy are easily accessible in India without proper medical oversight, as semaglutide goes off-patent next month with prices expected to drop 70 percent.
US forces struck three alleged drug-trafficking vessels on Monday, killing 11 people and bringing the total death toll to at least 145 since September in 42 known strikes across Latin American waters.
The European Medicines Agency recommended conditional marketing authorization for Anktiva in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer in December 2025.
Novo Nordisk confronts rising generic threats to its semaglutide-based drugs while navigating FDA scrutiny and legal challenges. The company advances oral semaglutide into pediatric diabetes care as competitors prepare to launch imitations.
Pharmaceutical companies are deploying AI and machine learning across clinical trial execution, regulatory submissions, and drug discovery to address rising costs and lengthy timelines in drug development.
Alvotech announced successful clinical trial results for AVT80, a biosimilar to Takeda's Entyvio, meeting all primary endpoints. The company targets a $6.4 billion market opportunity with regulatory submissions planned.
UK and Brazil issue warnings about possible pancreatitis link to GLP-1 weight-loss drugs, while WADA monitors their use in Olympic athletes amid concerns about muscle loss and performance effects.
The European Commission granted conditional marketing authorization for ANKTIVA plus BCG to treat BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, marking the first approved immunotherapy for this indication in Europe.
Immatics received FDA orphan drug designation for its melanoma therapy targeting Stage II and higher cutaneous melanoma in HLA-A 02:01-positive patients, marking a regulatory milestone that brings potential market exclusivity benefits.
A newly published study in Int. J. Mol. Sci. confirms that deuterium concentration directly influences gene expression in lung adenocarcinoma cells, validating HYD LLC's three-decade research on deuterium-depleted water as a complementary cancer therapy.
Ultragenyx Pharmaceutical received an Incomplete Response Letter from the FDA for its UX111 gene therapy resubmission for Sanfilippo syndrome type A, requesting additional documentation. The company announced a 10% workforce reduction and expects profitability by 2027.
New research and precision radiation techniques aim to minimize debilitating side effects of head and neck cancer treatment, including oral mucositis, while maintaining tumor control and improving patient quality of life.
